Advances in supportive care for multiple myeloma | Artur Jurczyszyn, MD

Advances in supportive care for multiple myeloma | Artur Jurczyszyn, MD

Hypomethylating agent for newly diagnosed TP53-mutant AML | Talher Badar, MBBS, MD

Hypomethylating agent for newly diagnosed TP53-mutant AML | Talher Badar, MBBS, MD

Can Epcoritamab Improve Outcomes in R-mini-CHOP Patients? | Chan Cheah, MD, PhD

Can Epcoritamab Improve Outcomes in R-mini-CHOP Patients? | Chan Cheah, MD, PhD

How Race & Social Deprivation Shape Myeloma Outcomes | Hamza Hashmi, MD & Paul Gater

How Race & Social Deprivation Shape Myeloma Outcomes | Hamza Hashmi, MD & Paul Gater

Stem Cell Boost vs Supportive Care for Prolonged Cytopenias After CAR-T | Cindy Varga, MD

Stem Cell Boost vs Supportive Care for Prolonged Cytopenias After CAR-T | Cindy Varga, MD

Cilta-Cel Outside Specs: How Safe & Effective Is It in Relapsed Myeloma? | Azra Borogovac, MD

Cilta-Cel Outside Specs: How Safe & Effective Is It in Relapsed Myeloma? | Azra Borogovac, MD

Treating Plasma Cell Leukemia: New Insights on Bispecific Antibodies | Mahmoud Gaballa, MD

Treating Plasma Cell Leukemia: New Insights on Bispecific Antibodies | Mahmoud Gaballa, MD

Myeloma Maintenance: Daratumumab as an Alternative to Lenalidomide | Sridevi Rajeeve, MD

Myeloma Maintenance: Daratumumab as an Alternative to Lenalidomide | Sridevi Rajeeve, MD

Bispecific Therapies in Myeloma: Preferences & Priorities | Thomas LeBlanc, MD

Bispecific Therapies in Myeloma: Preferences & Priorities | Thomas LeBlanc, MD

AI Assistant for Faster, Cleaner Data | JP Capdevila

AI Assistant for Faster, Cleaner Data | JP Capdevila

Fitness analysis of Isa-VRD transplant ineligible myeloma patients | Enrique Ocio, MD

Fitness analysis of Isa-VRD transplant ineligible myeloma patients | Enrique Ocio, MD

Circulating tumor cells (CTCs) improve myeloma risk stratification | Mattia D'Agostino, MD

Circulating tumor cells (CTCs) improve myeloma risk stratification | Mattia D'Agostino, MD